Washington, DC — December 9, 2025 — Leads & Copy — A federal indictment against former DEA Deputy Chief Paul Campo reveals allegations of narcoterrorism, money laundering, and cocaine trafficking, raising concerns about systemic corruption within the Drug Enforcement Administration. The indictment coincides with the DEA’s ongoing obstruction of MMJ International Holding’s FDA-sanctioned clinical trial program for Huntington’s Disease, now in its seventh year.
U.S. Attorney Jay Clayton and DEA Administrator Terrance Cole announced the charges against Campo and his co-conspirator, Robert Sensi, a former CIA operative. The charges include laundering up to $12 million in cartel drug proceeds, converting cash into cryptocurrency, facilitating a 220-kilogram cocaine transaction worth $5 million, and exploring the purchase of AR-15s, M16s, grenade launchers, and explosives. Campo is also accused of using his DEA position to assist cartel operatives and flashing his DEA badge during negotiations.
Prosecutors assert that Campo’s actions were a systematic betrayal of his 25-year career with the DEA, and the agency acknowledges that at least 16 agents have faced criminal charges in recent years. This indictment highlights the DEA’s vulnerability to cartel infiltration.
Simultaneously, the DEA has blocked MMJ BioPharma Cultivation from manufacturing natural cannabis extracts for FDA-authorized clinical trials for Huntington’s Disease and Multiple Sclerosis for seven years. MMJ has faced demands for a “bona fide supply agreement” prior to licensure, a requirement deemed impossible due to federal law prohibiting such agreements until after licensure. The company was also subjected to a DEA administrative hearing in 2024, which the Department of Justice now admits was unconstitutional. Federal statute requires the DEA to process research applications within 60 days, a deadline unmet for MMJ’s application after seven years.
A Yale Law Journal analysis suggests that the scientific division of power within the Controlled Substances Act has collapsed, subordinating science to ideology, with the DEA making unauthorized medical decisions.
MMJ CEO Duane Boise stated, “The DEA cannot claim authority over public safety while simultaneously blocking the only safe, FDA-regulated alternative to the products causing national concern. Patients with Huntington’s Disease and Multiple Sclerosis are paying the price.”
As Congress considers re-criminalizing intoxicating hemp derivatives, public health leaders are advocating for scientific oversight, which MMJ BioPharma aims to provide through standardized pharmaceutical dosing, GMP manufacturing, FDA clinical oversight, non-intoxicating formulations, and a fully legal federal pathway.
With the medicine and clinical trials prepared, the DEA’s signature is the only missing element. Administrator Terrance Cole is urged to issue MMJ BioPharma’s Final Order Now to restore scientific integrity and protect American patients.
MMJ International Holdings is a U.S. based biopharmaceutical company developing natural, plant-derived cannabinoid medicines for FDA approval. Its subsidiaries – MMJ BioPharma Cultivation and MMJ BioPharma Labs – operate under federal law to advance pharmaceutical soft-gel cannabinoid formulations targeting Huntington’s Disease and Multiple Sclerosis.
MMJ is represented by attorney Megan Sheehan.
Contact:
Madison Hisey
MHisey@mmjih.com
203-231-8583
Source: MMJ International Holdings
